Quantcast
Channel: All News Releases
Viewing all articles
Browse latest Browse all 1908

Fenway Health Commends PUSPOSE 2 Twice Yearly HIV Pre-Exposure Prophylaxis (PrEP) Injection Study Results

$
0
0

Gilead announced today that the PURPOSE 2 study of twice yearly lenacapavir injections as pre-exposure prophylaxis (PrEP) reduced HIV infections by 96% compared to daily oral PrEP. Fenway Health was a PURPOSE 2 study trial site. BOSTON, Sept. 12, 2024 /PRNewswire-PRWeb/ -- Gilead...


Viewing all articles
Browse latest Browse all 1908

Trending Articles